# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary art...
Oppenheimer analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announce...
Goldman Sachs analyst Paul Choi maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $8 price target.
HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization o...